Press Release
Second Quarter 2016 Highlights
- Revenue increased 16.4% to
$236.2 million , or 16.1% on a constant currency basis; - GAAP operating profit margin of 25.4%; Non-GAAP operating profit margin up 60 basis points from prior year to 15.9%;
- GAAP diluted earnings per share of
$0.57 ; Non-GAAP diluted earnings per share up 28% from prior year to$0.40 ; and - Acquired Biotronic NeuroNetwork to support spine service line partnership offerings.
"
A full reconciliation of GAAP to non-GAAP measures can be found in the tables of this news release.
Second Quarter 2016 Results
For the second quarter 2016, GAAP and non-GAAP gross profit was
During the second quarter, the Company elected to early adopt the new FASB Accounting Standards Update (ASU) for employee share-based payment accounting ahead of the mandatory 2017 effective date for all U.S. public companies. The Company adopted the ASU in the second quarter 2016, effective from
On a non-GAAP basis, the Company reported net income of
Cash, cash equivalents and short and long-term marketable securities were approximately
Annual Guidance for 2016
The Company provided the following updated projections to its full year 2016 guidance, which contemplates the impact of the Company's performance for the first half of 2016, the acquisition of Biotronic NeuroNetwork and the impact from the adoption of the ASU for employee share-based payment accounting, as well as expected changes in foreign currency rates:
- Revenue of approximately
$962.0 million , which includes a$1 million benefit from currency or approximately 18.6% growth compared to revenue of$811.1 million for 2015; versus a prior expectation of$928.0 million for 2016; - Non-GAAP diluted earnings per share of approximately
$1.64 , an increase of approximately 25.0% compared to non-GAAP diluted earnings per share of$1.31 for 2015; versus a prior expectation of$1.48 for 2016; - Non-GAAP operating profit margin of approximately 16.0%, an increase of 60 basis points compared to 15.4% for 2015; versus a prior expectation of approximately 15.8% for 2016;
- Adjusted EBITDA margin of approximately 25.4%, an increase of approximately 20 basis points, in line with the prior expectation, compared to 25.2% for 2015; and
- Non-GAAP effective tax expense rate of approximately 37%; versus a prior expectation of approximately 41% for 2016.
Supplementary Financial Information
For additional financial detail, please visit the Investor Relations section at www.nuvasive.com to access Supplementary Financial Information.
| Reconciliation of Full Year EPS Guidance | |||||||||||||
| 2016 Guidance | |||||||||||||
| 2015 Actuals | Prior 1, 2 | Current 1, 3 | |||||||||||
| GAAP net income per share | $ | 1.26 | $ | 0.20 | $ | 0.84 | |||||||
| Impact of change from basic to diluted share count | 0.03 | - | 0.03 | ||||||||||
| GAAP net income per share, adjusted to diluted Non-GAAP share count | $ | 1.30 | $ | 0.20 | $ | 0.88 | |||||||
| Litigation liability gain | (0.82 | ) | - | (0.83 | ) | ||||||||
| Business transition costs 4 | 0.27 | 0.19 | 0.20 | ||||||||||
| Non-cash interest expense on convertible notes | 0.31 | 0.38 | 0.38 | ||||||||||
| Non-cash purchase accounting adjustments on acquisitions 5 | - | 0.29 | 0.28 | ||||||||||
| Loss on repurchase of convertible notes | - | 0.34 | 0.34 | ||||||||||
| Amortization of intangible assets | 0.24 | 0.76 | 0.73 | ||||||||||
| In-process research & development | 0.02 | - | - | ||||||||||
| Tax effect of adjustments 6 | (0.01 | ) | (0.69 | ) | (0.34 | ) | |||||||
| Non-GAAP earnings per share | $ | 1.31 | $ | 1.48 | $ | 1.64 | |||||||
| GAAP Weighted shares outstanding - basic | 48,687 | 49,984 | 50,004 | ||||||||||
| Non-GAAP Weighted shares outstanding - diluted | 51,110 | 51,335 | 52,000 | ||||||||||
| 1 Prior guidance provided April 26, 2016. Current guidance reflects guidance provided July 26, 2016, as updated for the anticipated impact of the Biotronic Neuronetwork acquisition, the adoption of ASU 2016-09 Stock Compensation, as well as expected changes in currency. | |||||||||||||
| 2 Effective tax expense rate of ~63% applied to GAAP earnings and ~41% applied to Non-GAAP earnings. | |||||||||||||
| 3 Effective tax expense rate of ~41% applied to GAAP earnings and ~37% applied to Non-GAAP earnings. | |||||||||||||
| 4 Costs related to acquisition, integration and business transition activities which include severance, relocation, consulting, leasehold exit costs, third party merger and acquisitions costs and other costs directly associated with such activities. | |||||||||||||
| 5 Represents costs associated with non-cash purchase accounting adjustments, such as acquired inventory fair market value adjustments, which are amortized over the period in which underlying products are sold. | |||||||||||||
| 6 The impact on results from taxes include tax effecting the adjustments above at the statutory rate as well as taking into account discrete items and including those discrete items in the annual effective tax rate calculation. The Company also includes those adjustments that would have benefited the tax rate in lieu of the above adjustments as part of the Company's tax filings. The impact of the changes to the tax rate results in an annual estimated rate of ~37% on a non-GAAP basis. The Company adopted ASU 2016-09 Stock Compensation in Q2 2016 which was effective as of January 1, 2016 with retrospective adjustment. The result of the retrospective adjustment resulted in a change in the Q1 2016 quarterly effective tax rate on a non-GAAP basis from 41% to 36%. | |||||||||||||
| Reconciliation of Non-GAAP Operating Margin % | |||||||||
| 2016 Guidance | |||||||||
| (in thousands, except %) | 2015 Actuals | Prior 1 | Current 1 | ||||||
| Non-GAAP Gross Margin % [A] | 76.0% | 77.4% | 76.4% | ||||||
| Non-cash purchase accounting adjustments on acquisitions 2 | 0.0% | (1.6% | ) | (1.5% | ) | ||||
| GAAP Gross Margin [B] | 76.0% | 75.8% | 74.9% | ||||||
| GAAP & Non-GAAP Sales, Marketing & Administrative Expense [C] | 56.4% | 56.0% | 55.4% | ||||||
| Non-GAAP Research & Development Expense [D] | 4.3% | 5.6% | 5.1% | ||||||
| In-process research & development | 0.1% | 0.0% | 0.0% | ||||||
| GAAP Research & Development Expense [E] | 4.4% | 5.6% | 5.1% | ||||||
| Litigation liability [F] | (5.2% | ) | 0.0% | (4.5% | ) | ||||
| Amortization of intangible assets [G] | 1.5% | 4.2% | 4.0% | ||||||
| Business transition costs [H] 3 | 1.7% | 1.3% | 1.2% | ||||||
| Non-GAAP Operating Margin % [A - C - D] | 15.4% | 15.8% | 16.0% | ||||||
| GAAP Operating Margin % [B - C - E - F - G - H] | 17.1% | 8.7% | 13.7% | ||||||
| 1 Prior guidance provided April 26, 2016. Current guidance reflects guidance provided July 26, 2016, as updated for the anticipated impact of the Biotronic Neuronetwork acquisition, the adoption of ASU 2016-09 Stock Compensation, as well as expected changes in currency. | |||||||||
| 2 Represents costs associated with non-cash purchase accounting adjustments, such as acquired inventory fair market value adjustments, which are amortized over the period in which underlying products are sold. | |||||||||
| 3 Costs related to acquisition, integration and business transition activities which include severance, relocation, consulting, leasehold exit costs, third party merger and acquisitions costs and other costs directly associated with such activities. | |||||||||
| Reconciliation of EBITDA % | |||||||||
| 2016 Guidance | |||||||||
| (in thousands, except %) | 2015 Actuals | Prior 1 | Current 1 | ||||||
| Net Income / (Loss) | 8.2% | 1.1% | 4.7% | ||||||
| Interest (income) / expense, net | 3.4% | 6.1% | 5.9% | ||||||
| Provision for income taxes | 5.8% | 1.7% | 3.2% | ||||||
| Depreciation and amortization 2 | 8.1% | 10.9% | 10.5% | ||||||
| EBITDA | 25.5% | 19.8% | 24.3% | ||||||
| Non-cash stock based compensation | 3.1% | 3.0% | 2.9% | ||||||
| Business transition costs 2 | 1.7% | 1.1% | 1.1% | ||||||
| Non-cash purchase accounting adjustments on acquisitions 3 | 0.0% | 1.6% | 1.5% | ||||||
| In-process research & development | 0.1% | 0.0% | 0.0% | ||||||
| Litigation liability gain | (5.2% | ) | 0.0% | (4.5% | ) | ||||
| Adjusted EBITDA | 25.2% | 25.4% | 25.4% | ||||||
| 1 Prior guidance provided April 26, 2016. Current guidance reflects guidance provided July 26, 2016, as updated for the anticipated impact of the Biotronic Neuronetwork acquisition, the adoption of ASU 2016-09 Stock Compensation, as well as expected changes in currency. | |||||||||
| 2 Costs related to acquisition, integration and business transition activities which include severance, relocation, consulting, leasehold exit costs, third party merger and acquisitions costs and other costs directly associated with such activities. | |||||||||
| 3 Represents costs associated with non-cash purchase accounting adjustments, such as acquired inventory fair market value adjustments, which are amortized over the period in which underlying products are sold. | |||||||||
Reconciliation of Non-GAAP Information
Management uses certain non-GAAP financial measures such as non-GAAP earnings per share, non-GAAP net income, non-GAAP operating expenses and non-GAAP operating profit margin, which exclude amortization of intangible assets, purchase accounting related charges, leasehold related charges, integration related expenses associated with acquired businesses, one-time restructuring and acquisition related items, CEO transition related costs, certain litigation charges, non-cash interest expense and/or losses on convertible notes, and the impact from taxes related to these items, including those taxes that would have occurred in lieu of these items. Management also uses certain non-GAAP measures which are intended to exclude the impact of foreign exchange currency fluctuations. The measure constant currency is the use of an exchange rate that eliminates fluctuations when calculating financial performance numbers.
The Company also uses measures such as free cash flow, which represents cash flow from operations less cash used in the acquisition and disposition of capital. Additionally, the Company uses an adjusted EBITDA measure which represents earnings before interest, taxes, depreciation and amortization and excludes the impact of stock-based compensation, purchase accounting related changes, leasehold related charges, integration related expenses associated with acquired businesses, CEO transition related costs, certain litigation liabilities, acquisition related items and other significant one-time items. Management calculates the non-GAAP financial measures provided in this earnings release excluding these costs and uses these non-GAAP financial measures to enable it to further and more consistently analyze the period-to-period financial performance of its core business operations. Management believes that providing investors with these non-GAAP measures gives them additional information to enable them to assess, in the same way management assesses, the Company's current and future continuing operations. These non-GAAP measures are not in accordance with, or an alternative for, GAAP, and may be different from non-GAAP measures used by other companies. Set forth below are reconciliations of the non-GAAP financial measures to the comparable GAAP financial measure.
| Reconciliation of Second Quarter 2016 Results | |||||||||
| GAAP Net Income per Share to Non-GAAP Earnings per Share | |||||||||
| (in thousands, except per share data) | Adjustments | Diluted Earnings Per Share | |||||||
| GAAP net income | $ | 30,213 | $ | 0.57 | |||||
| Litigation liability gain | (43,310 | ) | |||||||
| Business transition costs 1 | 2,756 | ||||||||
| Non-cash interest expense on convertible notes | 5,051 | ||||||||
| Non-cash purchase accounting adjustments on acquisitions 2 | 7,374 | ||||||||
| Amortization of intangible assets | 10,281 | ||||||||
| Tax effect of adjustments 3 | 8,255 | ||||||||
| Adjustments to GAAP net income | (9,593 | ) | (0.17 | ) | |||||
| Non-GAAP earnings | $ | 20,620 | 0.40 | ||||||
| GAAP weighted shares outstanding - diluted | 53,159 | ||||||||
| Non-GAAP weighted shares outstanding - diluted | 51,928 | ||||||||
| 1 Costs related to acquisition, integration and business transition activities which include severance, relocation, consulting, leasehold exit costs, third party merger and acquisitions costs and other costs directly associated with such activities. | |||||||||
| 2 Represents costs associated with non-cash purchase accounting adjustments, such as acquired inventory fair market value adjustments, which are amortized over the period in which underlying products are sold. | |||||||||
| 3 The impact on results from taxes include tax effecting the adjustments above at the statutory rate as well as taking into account discrete items and including those discrete items in the annual effective tax rate calculation. The Company also includes those adjustments that would have benefited the tax rate in lieu of the above adjustments as part of the Company's tax filings. The impact of the changes to the tax rate results in an annual estimated rate of 36.5% on a non-GAAP basis. The result of these adjustments is a change in the quarterly effective tax rate from 40% to 37%. | |||||||||
| Reconciliation of Year To Date 2016 Results | ||||||||
| GAAP Net Income per Share to Non-GAAP Earnings per Share | ||||||||
| (in thousands, except per share data) | Adjustments | Diluted Earnings Per Share | ||||||
| GAAP net income | $ | 26,845 | $ | 0.51 | ||||
| Litigation liability gain | (43,310 | ) | ||||||
| Business transition costs 1 | 8,063 | |||||||
| Non-cash interest expense on convertible notes | 9,361 | |||||||
| Non-cash purchase accounting adjustments on acquisitions 2 | 12,290 | |||||||
| Loss on repurchases of convertible notes | 17,444 | |||||||
| Amortization of intangible assets | 17,830 | |||||||
| Tax effect of adjustments 3 | (10,749 | ) | ||||||
| Adjustments to GAAP net income | 10,929 | 0.22 | ||||||
| Non-GAAP earnings | $ | 37,774 | $ | 0.73 | ||||
| GAAP weighted shares outstanding - diluted | 52,354 | |||||||
| Non-GAAP weighted shares outstanding - diluted | 51,443 | |||||||
| 1 Costs related to acquisition, integration and business transition activities which include severance, relocation, consulting, leasehold exit costs, third party merger and acquisitions costs and other costs directly associated with such activities. | ||||||||
| 2 Represents costs associated with non-cash purchase accounting adjustments, such as acquired inventory fair market value adjustments, which are amortized over the period in which underlying products are sold. | ||||||||
| 3 The impact on results from taxes include tax effecting the adjustments above at the statutory rate as well as taking into account discrete items and including those discrete items in the annual effective tax rate calculation. The Company also includes those adjustments that would have benefited the tax rate in lieu of the above adjustments as part of the Company's tax filings. The impact of the changes to the tax rate results in an annual estimated rate of 36.5% on a non-GAAP basis. The result of these adjustments is a change in the annual effective tax rate from 29% to 36.5%. The Company adopted ASU 2016-09 Stock Compensation in Q2 2016 which was effective as of January 1, 2016 with retrospective adjustment. The result of the retrospective adjustment resulted in a change in the Q1 2016 quarterly effective tax rate on a non-GAAP basis from 41% to 36%. | ||||||||
| Reconciliation of Second Quarter and Six Months 2016 Results | |||||||||
| GAAP net income to Adjusted EBITDA | |||||||||
| Three months ended | Six months ended | ||||||||
| (in thousands, except per share data) | June 30, 2016 | June 30, 2016 | |||||||
| GAAP net income | $ | 30,213 | $ | 26,845 | |||||
| Interest (income) / expense, net 1 | 10,131 | 35,719 | |||||||
| Provision for income taxes | 19,891 | 10,411 | |||||||
| Depreciation and amortization | 24,813 | 45,707 | |||||||
| EBITDA | $ | 85,048 | $ | 118,682 | |||||
| Litigation liability gain | (43,310 | ) | (43,310 | ) | |||||
| Business transition costs 2 | 2,756 | 8,063 | |||||||
| Non-cash purchase accounting related charges 3 | 7,374 | 12,290 | |||||||
| Non-cash stock based compensation | 7,865 | 12,357 | |||||||
| Adjusted EBITDA | $ | 59,733 | $ | 108,082 | |||||
| As a percentage of revenue | 25.3% | 23.9% | |||||||
| 1 Included in Interest (income) / expense, net for the six months ended June 30, 2016 is loss on extinguishment of debt for $17.4 million. | |||||||||
| 2 Costs related to acquisition, integration and business transition activities which include severance, relocation, consulting, leasehold exit costs, third party merger and acquisitions costs and other costs directly associated with such activities. | |||||||||
| 3 Represents costs associated with non-cash purchase accounting adjustments, such as acquired inventory fair market value adjustments, which are amortized over the period in which underlying products are sold. | |||||||||
Investor Conference Call
About
| NuVasive, Inc. | ||||||||||||||||||
| Consolidated Statements of Operations | ||||||||||||||||||
| (in thousands, except per share data) | ||||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||||
| (unaudited) | 2016 | 2015 | 2016 | 2015 | ||||||||||||||
| Revenue | $ | 236,210 | $ | 202,910 | $ | 451,314 | $ | 395,293 | ||||||||||
| Cost of goods sold (excluding below amortization of intangible assets) | 59,745 | 48,415 | 113,971 | 94,079 | ||||||||||||||
| Gross profit | 176,465 | 154,495 | 337,343 | 301,214 | ||||||||||||||
| Operating expenses: | ||||||||||||||||||
| Sales, marketing and administrative | 134,487 | 114,680 | 259,325 | 227,889 | ||||||||||||||
| Research and development | 11,871 | 8,774 | 22,500 | 18,038 | ||||||||||||||
| Amortization of intangible assets | 10,603 | 2,974 | 18,474 | 5,970 | ||||||||||||||
| Litigation liability (gain) loss | (43,310 | ) | 568 | (43,310 | ) | (42,007 | ) | |||||||||||
| Business transition costs | 2,756 | 1,636 | 8,063 | 9,896 | ||||||||||||||
| Total operating expenses | 116,407 | 128,632 | 265,052 | 219,786 | ||||||||||||||
| Interest and other expense, net: | ||||||||||||||||||
| Interest income | 406 | 344 | 734 | 763 | ||||||||||||||
| Interest expense | (10,537 | ) | (7,242 | ) | (19,009 | ) | (14,368 | ) | ||||||||||
| Loss on repurchases of convertible notes | - | - | (17,444 | ) | - | |||||||||||||
| Other (loss) income, net | (246 | ) | (281 | ) | (196 | ) | 143 | |||||||||||
| Total interest and other expense, net | (10,377 | ) | (7,179 | ) | (35,915 | ) | (13,462 | ) | ||||||||||
| Income before income taxes | 49,681 | 18,684 | 36,376 | 67,966 | ||||||||||||||
| Income tax expense | (19,891 | ) | (8,644 | ) | (10,411 | ) | (26,529 | ) | ||||||||||
| Consolidated net income | $ | 29,790 | $ | 10,040 | $ | 25,965 | $ | 41,437 | ||||||||||
| Add back net loss attributable to non-controlling interests | $ | (423 | ) | $ | (228 | ) | $ | (880 | ) | $ | (391 | ) | ||||||
| Net income attributable to NuVasive, Inc. | $ | 30,213 | $ | 10,268 | $ | 26,845 | $ | 41,828 | ||||||||||
| Net income per share attributable to NuVasive, Inc.: | ||||||||||||||||||
| Basic | $ | 0.60 | $ | 0.21 | $ | 0.54 | $ | 0.87 | ||||||||||
| Diluted | $ | 0.57 | $ | 0.20 | $ | 0.51 | $ | 0.81 | ||||||||||
| Weighted average shares outstanding: | ||||||||||||||||||
| Basic | 50,027 | 48,545 | 49,822 | 48,269 | ||||||||||||||
| Diluted | 53,159 | 51,681 | 52,354 | 51,700 | ||||||||||||||
| NuVasive, Inc. | ||||||||||
| Consolidated Balance Sheets | ||||||||||
| (in thousands, except par values and share amounts) | ||||||||||
| June 30, 2016 | December 31, 2015 | |||||||||
| ASSETS | (Unaudited) | |||||||||
| Current assets: | ||||||||||
| Cash and cash equivalents | $ | 263,082 | $ | 192,339 | ||||||
| Short-term marketable securities | 54,081 | 165,423 | ||||||||
| Accounts receivable, net of allowances of $6,066 and $5,320, respectively | 141,917 | 127,595 | ||||||||
| Inventory, net | 201,901 | 168,140 | ||||||||
| Prepaid income taxes | 42,852 | 40,540 | ||||||||
| Prepaid expenses and other current assets | 8,141 | 8,790 | ||||||||
| Total current assets | 711,974 | 702,827 | ||||||||
| Property and equipment, net | 171,291 | 141,441 | ||||||||
| Long-term marketable securities | 13,654 | 112,332 | ||||||||
| Intangible assets, net | 263,607 | 85,076 | ||||||||
| Goodwill | 405,569 | 154,281 | ||||||||
| Deferred tax assets | 14,698 | 83,691 | ||||||||
| Restricted cash and investments | 7,403 | 5,615 | ||||||||
| Other assets | 17,714 | 17,404 | ||||||||
| Total assets | $ | 1,605,910 | $ | 1,302,667 | ||||||
| LIABILITIES AND EQUITY | ||||||||||
| Current liabilities: | ||||||||||
| Accounts payable and accrued liabilities | $ | 100,791 | $ | 60,985 | ||||||
| Accrued payroll and related expenses | 35,268 | 37,641 | ||||||||
| Litigation liabilities | 45,140 | - | ||||||||
| Income tax liabilities | 1,083 | 990 | ||||||||
| Short term senior convertible notes | 119,451 | - | ||||||||
| Total current liabilities | 301,733 | 99,616 | ||||||||
| Long term senior convertible notes | 555,493 | 372,920 | ||||||||
| Long-term acquisition-related liabilities | - | |||||||||
| Deferred and income tax liabilities, non-current | 14,288 | 8,602 | ||||||||
| Non-current litigation liabilities | - | 88,261 | ||||||||
| Other long-term liabilities | 26,541 | 14,425 | ||||||||
| Commitments and contingencies | ||||||||||
| Stockholders' equity: | ||||||||||
| Preferred stock, $0.001 par value; 5,000,000 shares authorized, none outstanding | - | - | ||||||||
| Common stock, $0.001 par value; 120,000,000 shares authorized at June 30, 2016 and December 31, 2015, 54,868,373 and 52,616,471 issued and outstanding at June 30, 2016 and December 31, 2015, respectively | 55 | 53 | ||||||||
| Additional paid-in capital | 1,017,902 | 989,387 | ||||||||
| Accumulated other comprehensive loss | (6,351 | ) | (12,112 | ) | ||||||
| Accumulated deficit | (77,161 | ) | (104,006 | ) | ||||||
| Treasury stock at cost; 4,681,346 shares and 3,316,794 shares at June 30, 2016 and December 31, 2015, respectively | (233,019 | ) | (161,788 | ) | ||||||
| Total NuVasive, Inc. stockholders' equity | 701,426 | 711,534 | ||||||||
| Non-controlling interests | 6,429 | 7,309 | ||||||||
| Total equity | $ | 707,855 | $ | 718,843 | ||||||
| Total liabilities and equity | $ | 1,605,910 | $ | 1,302,667 | ||||||
| NuVasive, Inc. | ||||||||||||
| Consolidated Statements of Cash Flows | ||||||||||||
| (in thousands) | ||||||||||||
| Six Months Ended June 30, | ||||||||||||
| 2016 | 2015 | |||||||||||
| (unaudited) | ||||||||||||
| Operating activities: | ||||||||||||
| Consolidated net income | $ | 25,965 | $ | 41,437 | ||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation and amortization | 46,329 | 32,630 | ||||||||||
| Loss on repurchases of convertible notes | 17,444 | - | ||||||||||
| Amortization of non-cash interest | 10,943 | 8,749 | ||||||||||
| Stock-based compensation | 12,357 | 13,493 | ||||||||||
| Reserves on current assets | 6,751 | 4,083 | ||||||||||
| Other non-cash adjustments | 8,387 | 10,669 | ||||||||||
| Deferred income taxes | 14,691 | 19,996 | ||||||||||
| Changes in operating assets and liabilities, net of effects from acquisitions: | ||||||||||||
| Accounts receivable | (8,615 | ) | 637 | |||||||||
| Inventory | (12,019 | ) | (15,181 | ) | ||||||||
| Prepaid expenses and other current assets | 728 | 1,182 | ||||||||||
| Accounts payable and accrued liabilities | 14,273 | 6,841 | ||||||||||
| Accrued royalties | 111 | (47,112 | ) | |||||||||
| Accrued payroll and related expenses | (4,356 | ) | (8,370 | ) | ||||||||
| Litigation liability | (43,310 | ) | 4,795 | |||||||||
| Income taxes | 10,534 | (38,666 | ) | |||||||||
| Net cash provided by operating activities | 100,213 | 35,183 | ||||||||||
| Investing activities: | ||||||||||||
| Acquisition of Ellipse Technologies, net of cash acquired | (380,080 | ) | - | |||||||||
| Other acquisitions and investments | (8,079 | ) | (1,357 | ) | ||||||||
| Purchases of intangible assets | (5,918 | ) | (28,589 | ) | ||||||||
| Purchases of property and equipment | (52,566 | ) | (47,976 | ) | ||||||||
| Purchases of marketable securities | (128,956 | ) | (129,549 | ) | ||||||||
| Proceeds from sales of marketable securities | 339,320 | 164,147 | ||||||||||
| Sales of restricted investments | - | 33,809 | ||||||||||
| Purchases of restricted investments | - | (62,625 | ) | |||||||||
| Net cash used in investing activities | (236,279 | ) | (72,140 | ) | ||||||||
| Financing activities: | ||||||||||||
| Incremental tax benefits related to stock-based compensation awards | - | 9,928 | ||||||||||
| Proceeds from the issuance of common stock | 6,150 | 8,360 | ||||||||||
| Payment of contingent consideration | - | (514 | ) | |||||||||
| Purchase of treasury stock | (22,549 | ) | (43,937 | ) | ||||||||
| Proceeds from issuance of convertible debt, net of issuance costs | 634,140 | - | ||||||||||
| Proceeds from sale of warrants | 44,850 | - | ||||||||||
| Purchase of convertible note hedge | (111,150 | ) | - | |||||||||
| Repurchases of convertible notes | (343,835 | ) | - | |||||||||
| Proceeds from revolving line of credit | 50,000 | - | ||||||||||
| Repayments on revolving line of credit | (50,000 | ) | - | |||||||||
| Other financing activities | (1,545 | ) | (87 | ) | ||||||||
| Net cash provided by (used in) financing activities | 206,061 | (26,250 | ) | |||||||||
| Effect of exchange rate changes on cash | 748 | (543 | ) | |||||||||
| Increase (decrease) in cash and cash equivalents | 70,743 | (63,750 | ) | |||||||||
| Cash and cash equivalents at beginning of period | 192,339 | 142,387 | ||||||||||
| Cash and cash equivalents at end of period | $ | 263,082 | $ | 78,637 | ||||||||
Investor Contact:
1-858-458-2240
Email contact
Media Contact:
1-858-909-1940
Email contact
Source: